Rates And Commodities Diverge… Plus Lilly’s Latest Drug Concerns 6/6/24

6 Jun 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" - Rates And Commodities Diverge… Plus Lilly’s Latest Drug Concerns (6/6/24)

Episode Overview In this episode of CNBC's "Fast Money," host Melissa Lee, alongside a panel of traders, discusses the recent movements in commodity prices, falling rates, and the implications for investors. The episode also dives into Eli Lilly's Alzheimer's treatment and the FDA's review process.

---

Key Topics Discussed

  1. Commodity Market Movements
  2. Current Trends:
  3. Commodities are experiencing a rise across various sectors including oil, metals, and agriculture.
  4. Specific commodities mentioned:
  5. Gold & Copper: Prices are increasing.
  6. Silver: Surged over 4%.
  7. Agricultural Goods: Corn, oats, soybeans, sugar, and orange juice prices are all higher.
  • Interest Rates:
  • Contrarily, interest rates are falling, with the 10-year yield down to 4.28%.
  • There are discussions about an imminent jobs report that could further influence market sentiment.
  • Trader Insights:
  • Tim Seymour: Highlights that commodity prices reflect demand and structural reasons, suggesting that monetary policy changes (like ECB rate cuts) are influencing commodities positively.
  • Lori Calvacina: Suggests that fundamentals in materials and a potential bottoming of the Chinese economy could further push commodity prices higher.
  1. Interest Rate Policy
  2. ECB Rate Cuts:
  3. The European Central Bank (ECB) has made a historic rate cut, leading to discussions about future Fed actions.
  4. The panel speculates a possible coordinated global easing cycle.
  • Market Reactions:
  • There are concerns about the implications of falling rates for stock prices and how bad news regarding jobs may be perceived negatively by the market.
  1. Eli Lilly's Alzheimer's Drug
  2. FDA Review:
  3. Eli Lilly's experimental Alzheimer's drug is facing scrutiny from the FDA, with concerns about the data's applicability to broader patient populations.
  4. There’s a comparative analysis with Biogen's drug, Lakembi, highlighting the ongoing challenges in Alzheimer's treatment development.
  • Market Impact:
  • The potential for Eli Lilly’s drug to reshape the Alzheimer’s treatment landscape is significant, depending on FDA approval.
  1. Stock Performances
  2. Walmart:
  3. Walmart hits an all-time high, driven by strong consumer demand amidst economic conditions.
  4. Discussion on whether higher-income consumers will continue to favor Walmart over competitors like Target.
  • NVIDIA:
  • NVIDIA's stock is under scrutiny due to potential regulatory actions affecting major players in the AI space, including itself, Microsoft, and OpenAI.
  • Robinhood:
  • Robinhood's acquisition of the crypto exchange Bitstamp is discussed as part of their strategy to expand in digital assets.
  1. Market Dynamics
  2. The interplay of commodity prices, interest rates, and stock performance is discussed extensively, with traders speculating on the future market trajectory amidst various economic pressures.

---

Key Takeaways

  • Commodity Market: There is a strong upward trend in commodity prices, driven by various global economic factors, signaling potential inflation.
  • Interest Rates: Falling interest rates may stimulate more commodity price growth, but could also lead to complicated market reactions to economic news.
  • Eli Lilly's Prospects: The future for Eli Lilly's Alzheimer's drug is uncertain and hinges significantly on FDA approval outcomes.
  • Investor Strategy: Traders are advised to consider the implications of current rate cuts and market signals when positioning themselves.

---

For further insights and discussions, tune into "Fast Money" weeknights at 5 PM ET on CNBC.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live from the Nasdaq market site in the heart of New York City's Times Square. This is Fast Lilly, the drugmaker, hitting another all-time high as it awaits an FDA decision on his Alzheimer's drug. Will it get the approval it's seeking, and what could it mean for the company? Plus, a new record high for Walmart. Shares of Robinhood take flight, and a stealth surge in the stock of the home goods retailer. I'm Melissa Lee coming to you live from Studio B at the NASDAQ on the desk tonight. Tim Seymour, Dan Nathan, Guy Adami, and Lori Calvacina, head of U.S. equity strategy at RBC Capital Markets.

0:45And on a day where the major markets are relatively flat, check out the big moves in commodities, metals and oil both jumping in today's session. Gold and copper in the green, silver surging more than 4 percent, and crude and bread both pumping higher. The agricultural space growing as well. Corn, oats, soybean, sugar, OJ, all higher. But as a commodity complex heads north, rates continue their recent downturn. Yields lower across the board. The 10 year now at 4.28 percent, while investors turn their attention to tomorrow's big jobs report. So what are these moves telling us about the markets right now?

1:19Tim, what do you say? Well, I think the commodities markets have been ticking higher all year. I think they've been ticking higher for a couple of years. I think there's structural reasons in the case of some of the metals, some of the industrial metals. And there's also fiscal reasons. There are budgetary reasons as it relates to precious metals. Oil, I think, has been remarkably stable. So we've had some volatility in oil over the last couple of weeks, more around OPEC, less around fundamentals. Although Paul Sankey was here last week and pointed out it's not so great when you're having this kind of price action going into the deepest demand part of the year.

1:48But but back to what I think commodities are doing on a day like today is I think they're sniffing out central banks. Today was symbolic. It was momentous. It was five years in the making. It was the first time the ECB has cut rates, whether the Fed cuts or not. The question is not now. Will they cut? It's what's the pathway to more cuts? And I think commodities will also sniff that out because perversely, again, they cut. But they pointed out that inflation is higher. They had kind of painted themselves into the wall, into the corner. And I think you have a case where commodities are going to show more signs of inflation.

2:17I don't think it's going to help. And I think the demand side is good enough to keep commodity prices higher. I stay long copper. I stay long miners. I certainly stay long gold. I agree with that. And, you know, people think commodities, the first thing they think of is crude oil. And we have seen a pretty dramatic sell-off today, notwithstanding. But there have been other things going on. And recently, some of these soft commodities and some of these industrial metals, copper, have sold off. The reason why I'm still encouraged is pull up a Freeport-McMoran chart, and you'll see that stock made a basically two-and-a-half-year high, but it really didn't pull back on the back of the copper sell-off, which leads me to believe there's more run in this.

2:52And I still think, you know, I don't want to say super cycle because I don't think that's what's going on, but I do think the ECB just opened the door, and I think at some point the Fed sort of kicks it in, and the commodities will continue to go higher. Coordinated global easing cycle, which is basically what we're starting now, Lori. No, I think that's right. And I think, you know, putting the rates issue aside, I think that what we're seeing with this commodity strength, we've been seeing it for a while on the material side. There are lots of fundamental longer term drivers there. We're also starting to hear in corners the idea that China may be bottoming.

3:22Things may be turning around a bit globally. You know, and it's interesting on the energy side. This doesn't really speak to the oil price, but I spent the last couple of days at our energy conference. And I will tell you, the tone was with stability and oil prices. Things look pretty good for these companies. And there was tremendous interest, tremendous demand. And really, you know, just, I think, reflects the idea as well that we're kind of mid-cycle, right? You know, that we're not sort of teetering on the edge of recession. And these are areas you want to look at. Yeah, the eurozone stuff is kind of interesting.

3:50So the ECB, we know that, you know, inflation is lower than it is over here. If you're looking at the equivalent of the CPI, I think it's like two and a half or so, somewhere around that. But we also are expecting lower growth over there, too. So I think Tim, the way he kind of, you know, kind of laid it out is they kind of painted themselves in a corner. I mean, the Fed keeps talking the other way, right? They still want to wait that they're sure that inflation is going to come down before they kind of cut rates or so. And if you think about just what we've seen with rates going from 4.65 in the 10-year down to, what, 4.28 or something right now, you look at the dollars come in 2.5 % or so during that time period.

4:24I mean, I just don't see any reason why the Fed needs to kind of get in front of this or kind of join the party, like you just called it a coordinated sort of rate-cutting cycle. We know that's ultimately going to come at some point. But if too much of these other zones, call them, start lowering interest rates and it kind of causes some of these metals or crude to kind of get back going again. And if you're talking about, you know, China, which is so far behind all of us bottoming, then you're going to see a lot of these commodities come back pretty quickly. And we just could find ourselves in this sort of, you know, virtuous sort of cycle.

4:54Yeah, I think it continues to be. I know this is a global show, so I'll be careful. where we actually have a global guest in the house, but are Fed your problem? And I think this is a case where it doesn't matter that the ECB led the way. It matters really what the Fed's going to do. The interesting thing here is, though, we talk about the commercial real estate market. We talk about certain corporates where at some point higher rates might break the back of certain credits. But how about governments? You know, and how about you start to look at the EU with slower growth and you start to wonder when at what point, when again in weakening growth, it's going to put pressure on the euro.

5:29And this is a long way away. I think. But it sets in motion issues that we've had, which are there are weaker credits across the European Union. Remember the pigs? Remember these countries that we were bailing out over and over and over again? The world right now has decent growth. Laurie's absolutely. We're mid cycle. The fact that matters, we also got some jobs, some some some labor cost data today that was very Fed friendly. It was very friendly in terms of where labor costs are. We have a huge payroll number tomorrow. And I think the more interesting thing for the market at all-time highs is, what do you do with weaker news on the payroll number?

6:01Is bad news bad news or is bad news good news? Because right now it's been a week where rates have really rallied and the stock market has obviously done the inverse. Well, answer the question, Ken. Well, I think bad news is going to be bad. I mean, if the unemployment rate ticks, I think expectations are still 3.9, right? And I try to pay attention, cheapest thing you can do. But you get a forehandle. I think sort of people start picking up their head and say, what's going on? Is this thing now trending the wrong way? I think the market's not going to react favorably to that. That's somewhat counterintuitive because bad news has been good news.

6:28I'll say this, though, quickly about the ECB. I also think they sort of threw in the towel because not only did they cut rates, they basically raised their inflation expectations. So I think effectively what this is, this is just my read. We understand it's probably out of our control. We have to do it anyway. And I think to a certain extent that might be happening here as well. I'm still one of the people, one of the few that think inflation is a problem. This was really a hawkish cut. I mean, Christine Lagarde was right. It had to be. Yeah, yeah, exactly. Exactly. And, you know, she was basically saying that we're just moving to a less restrict.

6:59It's still restrictive. We're just moving slightly less restrictive. And they sort of had to, given what's going on in Germany. Right. And look, I think overseas, right, we have different mortgage markets, right? The pressures of interest rates are being felt differently, you know, in different parts of the world and different consumer cohorts. But, you know, I think it's interesting as we sort of debate these Fed moves, we look at these commodity moves. As I talked to a lot of investors recently, they've come to terms with the idea that post-COVID inflation is going to run hotter than it ran before COVID and that we're simply going to have to get used to it.

7:28And it's not the end of the world. The tricky part is how do central banks navigate that? Right. But I think, you know, what I feel like we saw today in the price action was actually pretty healthy. Yeah. So what happens tomorrow? So let's sort of walk through this. We had something that's weaker. So what happened? What's the reaction? It was lower. And I think what Guy's saying here is that what does the stock market do with lower yields? Right. if we're on our way to 4.2 or something like that. In this context, though. Yeah, I mean, because really what it would say is that sooner or later they have to be less restrictive, which is what kind of we heard here.

7:56And I guess we could make the argument, you know, Laurie, you're a strategist. In our lifetimes, when you have Fed funds at 5.5%, you have CPI at 3.1%, that doesn't seem particularly restrictive, right? And we haven't seen really that long and variable lag yet where we've seen a meaningful slowdown. Just look at some of this ISM data. It really does fly in the face of some of the stuff that we've seen from the consumer over the last couple of weeks. So it's a pretty complicated case here. No, I think complicated is the right word. And if we just sort of take rates and inflation and think about the S &P, you know, we saw these weird sector moves today, right?

8:26But the market itself didn't really do a whole lot. One of the things we've seen on our valuation modeling is that 5 ,300 is about where we deserve to be at year end. If we see PCE go to 2.6, if we see 10-year yields go down to 4.19, if we see the Fed do one or two cuts, that's basically modeling in consensus expectations to our valuation model. and it goes, you know, I'll spare you all the details, but it goes all the way back to the 1960s, you know, so it bakes in a lot of different cycles. And I think that's why it's interesting in here. The market just kind of keeps hitting this 5 ,300 mark and just can't break out.

8:56Like, we had a good couple days this week. But there's a pressure point here, right? And I actually tend to agree with Guy. I think if we get bad news on the jobs number, I think that is interpreted as bad news because people have kind of come to terms with the idea that the Fed is not going to blow the economy. And if we start to see signs that that's happening, I think that's going to throw this whole thesis off. But so what do you do in a lower growth environment where the economy is not falling from the falling? The sky's not falling, falling out of bed, whatever, whatever metaphor. We don't want to mix, guy.

9:26We don't like to mix metaphors. No, you look at me because you're putting it on me. Actually, I know what you did. I see mixed metaphors. I never mix metaphors. I was really looking for a pat on the back because they're there. Anyway, you have a case here where I think the sectors that will continue to outperform are some of the ones that have already outperformed. But I think there's a place also for this broadening. First of all, I love utilities here. I love them for a secular. And we all know the kind of the power generation story is one that between EV and AI is, and just a grid and a thing that needs to be built out in this country, but lower rates are going to continue to have utilities outperform, which Carter has pointed out that over the last 20 years, actually utilities have outperformed the S &P when you throw in that dividend yield.

10:03So that's interesting. I think that the mega cap tech world where there's still his growth, and I know we complain in earnings season, And this is where 40 percent of the growth, the overall growth came from those four or five stocks. I think you have to stay there. So NVIDIA is going to be OK, right? Because that's what America wants. Well, I mean, look, folks, relax. Or it's like that scene in an airplane where they walk into the cockpit and they say to them, we're all counting on you. So that's what they're saying. We're all saying that to NVIDIA. Right now, I'm less worried about NVIDIA than I am worried about some other stocks and consumer discretionary in places where I think that COVID, that final unwind, And that long and variable lag of COVID and COVID demand and dynamics that pushed a lot of discretion.

10:43And we're going to have a great conversation later in the show about one stock in particular. Real quick, without maybe even realizing it, I think Jerome Powell may have, in trying to be glib and clever, he may have painted himself into a corner because when, remember that whole, I don't see the stag. Or inflation. Or the inflation, which is really, that's like, that's how funny I mean, it's cute. However, one of the things he talked about was the unemployment, right? Well, if you start to see a tick up in the unemployment rate, which obviously we're going to start to find out about prior to the meeting next week, he's going to then have to answer those questions that he sort of opened the door for.

11:15All right. Well, for more on the rate retreat, let's bring in Andy Constant. He's the CEO of Damped Spring Advisors. Andy, great to have you with us. All conversations end up leading to NVIDIA. And in fact, that's where this conversation is going to end up going. But before we get to that, what are you expecting in terms of the jobs report tomorrow and the reaction to the bond market? Yeah, I mean, I think we've had a pretty big inflection over the last, call it a week, with weakening growth numbers, weakening jobs numbers, survey data. And that's caused a bond market rally. And really, for the first time, that's been the root cause of a bond market rally.

11:52Prior to that, assets have been supported by disinflation that's been coming down since the peak and may not get all the way down, but has been a driver for assets. And the Fed being expected to withdraw restrictive conditions and ease. And so that's supported both stocks and bonds. while growth has been robust, strong growth for many quarters now. And that's been keeping pressure on bonds. And so we had an inflection this week where bonds rallied a lot on falling growth, not the drivers that have caused price returns lately. And so I think that's interesting. And it speaks to what you guys have been saying, which is, are we in a period of time in which the driver of asset prices is going to be the direction of growth?

12:49And if it's lower, that has implications for stocks, that they should also follow falling bond yields with falling stock prices. Where does NVIDIA fit into this? Well, NVIDIA is interesting. I know nothing about single names, but it is interesting in that This is the first year over my entire history of looking at individual years of stock market returns across global markets where a company has dominated the returns so much. This year, it's around 30 percent of the total return of stocks. The largest companies like Apple, Google, and prior to that, certain oil stocks have, and Microsoft, never really are more than 5 % to 10 % of the index.

13:42In this case, NVIDIA is the dominant factor in markets. And I think that's what's the best word? It's masking what's happening to macro equities in that over the course of the last since the earnings, the stock is up, what, 30 percent. And there may be I don't know, but tomorrow we'll start seeing the is the last day where the stock will trade pre split. it, it's possible that there's some fluff that is keeping NVIDIA high, which itself has been causing overall equity markets to be high. Now, again, I don't know if NVIDIA is cheap or rich right here, but it does seem that there's some undeserved fluff in the stock associated with the stock split.

14:33And if it falls post-split, that might unmask what is a weakening environment for stocks as growth becomes the driver. Supports bond prices, but bond prices have significant supply that's coming. Inflation may or may not be dead yet. And the valuation of bonds has gotten very low relative to the front end of the curve relative to cash. So it'll be an interesting inflection point. And that's really what we'll see in the data, the NFP tomorrow, the average hourly earnings. Then we have a raft of supply of long-term bonds next week, the FOMC and the dot plot. And then, of course, the CPI number. And so what I'm looking for is whether we will, in fact have an inflection.

15:28And what that would mean to me is continued support of bond prices while stock prices fall. So just quickly, Andy, give us the lowdown on how you're positioned at this point. You know, last time I was here, I was saying the market had topped at 52.60. I covered some when it fell in April, but I'm short again at this level. And I'm starting to short bonds because I don't think both assets can rally. So I think I'll make money on one side of that trade or possibly both. Andy, great to speak with you. Thank you. Andy Constan of Damped Spring. Do you agree with that? Both assets shouldn't be rallying right now.

16:07Well, I think we've seen a lot of this, right? It's not uncommon, the correlation that we've seen between these asset classes. I do think that the bond market is also, it's the rates market. It's also the credit markets. We've seen credit spreads get incredibly tight. In fact, you can make an argument we're as tight as we've been. And therefore, I actually worry about that in a lower rate environment. So I agree. You know, the math around the NVIDIA, I was crunching these numbers while Andy did it. Maybe everyone's already done this already. But again, 145 percent when it's 5 percent of the S &P ends up being about 720 basis points of 1 ,250 or 12 and a half percent that we've had.

16:44That's almost 55 to 60 percent of the return profile. That's a very linear exercise and it's not totally accurate, But it does tell you where you've gotten. Again, if you took 5 percent of the S &P up 145 percent, that tells you what NVIDIA does. I think I probably get there from a different on a different path. But I do sort of share the idea that, you know, stocks, even, you know, the price action we've seen this week, I just don't love. And I think in addition to our valuation work, the sentiment indicators are still looking pretty frothy at this point in time. Yeah. So on the NVIDIA, it's kind of interesting.

17:17Dan Niles, friend of the show. And, you know, I think he's a really smart tech investor. He put a tweet out today, and it's worth taking a look at. He said over the next three to four years, he expects revenues for NVIDIA to possibly double or triple, actually, from here. The street, excuse me, triple. The street, if you're looking at fiscal year 2028, 2029, is expecting it to be up, let's call it, 100%. So right now, you'd say consensus is really low. But he did say this, and I think this is really important. He says by the end of the year, he expects it to be a digestion period for AI spend.

17:48And so you tell me where the stock goes if you see a meaningful deceleration before another acceleration in a couple years for the next phase of this thing. I just don't know. I just know from, you know, the March highs to those lows, it sold off 20 percent. But it's since then gained one and a half trillion dollars in market cap in like two and a half months. I just think that there's a lot of it's different this time. And that's the thing that makes me a little nervous. All right. Meantime, Walmart hitting a new all time high today. This is a company holds its annual shareholder meeting in Bentonville, Arkansas.

18:16saw the stock has been on a run in 2024, jumping nearly 30 percent year to date, far outpacing its rival. Target, Guy, the higher income consumer. Will they stick to Target if the economy turns stick to Wal-Mart? Oh, excuse me. Yeah, no, I get the answer. And yes, I think the end with collectively, I think we've been saying that for quite some time. I mean, the environment that we find ourselves in, it works for Wal-Mart in ways they probably never imagined. And I think the The stock is reflecting that. Now, the naysayer will knock Walmart on valuation, and it probably is a tad rich. But you know what?

18:49I think it's deserved of that valuation, especially if the trajectory that I think is going on in terms of the consumer and the economy continues. That works for Walmart. I think you stay along the stock. Still unbelievably much lower than its five year high in terms of forward P. The five year high was like in 2022 and it was 54 or something like that. And it's earning a higher multiple because the margin profile of this company is changing and it's changing with their investment in digital and software and some of the dynamics around even the product mix. But think about where we were. I'm just I'm looking at a chart.

19:22Think about those inventory updates that we got from Walmart and Target and how different the world feels from that point. We're the smartest guys in retail, the smartest guys in terms of ERP and logistics and all the management. You know, October of 23 was one point. But really, as you went back into 22, this was a case where we were not sure that they were going to be able to turn this boat around. And they really have. So I'm long Walmart. The valuation doesn't bother me because I see it very defensive in an environment where I think we actually could see the market multiple pull back. I mean, what has five below what have the dollar stores really told us that is the lower consumer is really under duress.

19:59Right. And a lot of that is because of high interest rates. And the higher end consumer, right, has all these buffers, whether it's low mortgage rates, whether it's lots of cash sitting in money market funds. And by the way, if you look at those assets, they've absolutely ballooned in the last few years. So I think you do want to continue to follow the high end consumer. And to be honest, I'm hearing a lot about that on the road from investors. They're looking at this retail environment saying, look, the sector is starting to get some valuation appeal back. You can't just buy everything in the sector.

20:26You have to go with the ones that are executing and are in the right consumer cohorts. Yeah, so one of those companies that is executing on the retail front, and we haven't been able to say this for too long, if we were playing Would You Rather, I'd probably go with Amazon here. It's got a much higher growth rate. Were we playing that game? No, I wasn't. I don't remember saying let's play a game. In fact, I think we said tonight we weren't going to play that game. Anyway. So I'm playing. You can take your ball and go home, Jim. Okay. No, I just think it's really interesting. When you look at the margin structure, you look at how margins are going higher.

20:54A lot of that has to do with the improvement in the retail space here. Obviously, you have AWS, which is a huge part of that margin structure. It's kind of bottoming and should benefit from all this generative AI. So to me, I just look at the margins, the way they're increasing in Amazon. I find it more interesting than Walmart. Again, if you were playing that game. I think it's time to play. Let's go to commercial, Mel. Good game. Important game for us. I think it's a great game to play. Coming up, NVIDIA pulling back from record highs today. the potential regulatory hurdles facing the company and what they could mean for leadership in the AI race.

21:26Plus, Robinhood splashing the cash. The fintech title, Titan, shelling out a big chunk of change to buy crypto player Bitstamp. What to make of this deal next.

21:38This is Fast Money with Melissa Lee, right here on CNBC.

21:50Welcome back to Fast Money. Federal regulators are gearing up for an antitrust investigation into AI heavyweights, including Microsoft, NVIDIA, and OpenAI. For more on what the crackdown could mean for big tech, let's bring in CNBC's Eamon Jabbers. Eamon. Hey there, Melissa. Well, here's what we know as of right now. Multiple sources familiar confirmed to CNBC that the Department of Justice and the Federal Trade Commission are in the final stages of setting up a deal to divide up antitrust inquiries into NVIDIA, Microsoft and OpenAI, several of the most dominant players in this rapidly emerging AI space.

Read the full transcript

22:24Now, the deal, which was first reported by The New York Times this morning, largely covers investigations into the behavior of the companies, I'm told, not necessarily mergers and acquisitions by the companies. And I'm also told that the Department of Justice will look at Taiwanese chipmaker TSMC if there is any upcoming investigation. That also, according to a source familiar there. Now, because TSMC has operations in the United States, it does come under the Department of Justice's jurisdiction for those pieces of the business, even though it's based in Taiwan. Now, all of that signals that the U.S.

22:58government investigative effort will be focused on both the hardware and chip piece of the industry, as well as the software and large language model size side of the industry. And according to the terms of the deal that are under discussion between the DOJ and the FTC. DOJ is going to take the lead on investigating whether NVIDIA has violated any antitrust laws, and the FTC will lead examinations of OpenAI and Microsoft. Now, Melissa, what's still unknown in all this is what evidence, if any, the federal government would be able to produce to suggest any violations of the law by any of those companies.

23:33All of that work, still a long way off here. What looks like is going on here is maybe an effort to stave off a classic Washington turf war. You know, both of these agencies are resource deprived. And this way, if they can kind of carve up the industry, they can deploy the most assets at each target. If you're in the AI industry, though, that might be unwelcome news, Melissa. How do you read all of this, Eamon? I mean, if the investigation is going to focus on the hardware and chip side, but then sources say that it's going to focus on the behavior of the companies, put those two together for us in terms of what they could be investigating exactly.

24:11Yeah, I mean, so I think what you're looking at is anti-competitive practices outside the M &A world that are covered by this deal. So that doesn't mean necessarily acquiring smaller competitors. It means doing things in terms of contracts, licensing, employees, collusion, all those kinds of things are the kinds of anti-competitive things that government looks for here. But we We don't have an ounce of information of what evidence might be here, might be triggering all of this. You know, you would think that it wouldn't get to this point if they didn't have at least something to go on. We just don't know what that is, what the kernel of truth here is that's driving this at this point.

24:51So we just have to wait and see. All right. Amen. Thank you. Amen. Javers in Washington for us. We also don't know how long this could take because oftentimes these things take a very long time before anything happens. And so is this something investors in an NVIDIA or a Microsoft or an AI at large should really focus on right now? Well, if you look at the last five years, we've seen investigations of Amazon, Facebook, Google, Apple, and really they don't mean a whole heck of a lot. I would just say what's different about like focusing on these three companies right now is they're obviously some of the first movers in an area that is very different from, I think, you know, very different than the Internet.

25:29The Internet was going to be very disruptive, right? This has the potential to go at a much faster pace and have much bigger implications on every part of our society, not just industry and the like. So to keep these companies honest, I think it makes some sense. You know what I mean? I think that the DOJ and the FTC have clearly overstepped many of their bounds. They've not been able to prove monopolistic sort of behaviors in almost all of these sorts of situations. But hopefully this is something that does not thwart innovation in this country, Because that, I think, is the most important part of our economy right now going forward, that we own the innovation and generative AI.

26:03Well, there's a difference between being anti-competitive and kicking your competition's ass. And I think you heard me correctly. Well, you heard. I can't say it. But the point is, like, I think there's a belief that if companies are doing as well as these companies are, they must be, by definition, they must be doing something wrong. So I think they're trying to find guilt where there probably is just excellence. That's just my take. You think about the combined market cap of the top three companies in the world, and we know that their GDP is big. I mean, their combined market cap is bigger than the GDP of the entire world other than really ours.

26:38Now, what does that mean? It means that at some point these companies do have disproportionate influence on a global stage. And that's what regulators at least need to worry about in this country. I think there's a case where if you look at Europe, you can make an argument that the EU regulators have hurt European companies for decades. And if you think about companies that have been competing with Google and Microsoft, I think EU regulators have made it a lot more difficult for them. I think we need to be careful about that in this country. But I don't think it's going to affect the$2 billion fine against Apple recently.

27:09What does that mean? The word that keeps coming up in my conversations lately on AI is messy. And that's the first thing I thought of when I saw these headlines today, that we're in this. You've had this enormous run. You've had this big concentration. Everybody's playing this theme. We're starting to hear companies say, hey, it's going to take longer for this to hit our expense line. The growth rates, if you look at the basket of the MAG-7 as a whole, are decelerating. Decelerating earnings growth always makes people nervous. So you throw something like this in the mix, I think it just adds to that mess, adds to that nervousness, and encourages people to look elsewhere.

27:39There's a lot more Fast Money to come. Here's what's coming up next. Robinhood puts their stamp on crypto, the trading platform splashing the cash on crypto exchange Bitstamp. But will the big buy pay off? We'll peek under the hood of this latest land grab next. Plus, Eli Lilly in limbo ahead of a landmark hearing on the pharma giant's potential blockbuster Alzheimer's drug. The very first look inside the decision that could reshape the Alzheimer's treatment landscape. right after this. You're watching Fast Money from the Nasdaq market side in Times Square. We're back right after this.

28:25Welcome back to Fast Money. Robinhood topping the tape after splashing$200 million on crypto exchange Bitstamp. The deal is expected to close in the first half of 2025 and accelerates Robinhood's push into digital assets. Bitstamp, a 13-year-old platform popular in Europe and Asia, gives Robinhood a foothold abroad as it looks to build out its stable of assets. Robinhood now up more than 80 percent this year at its highest since December 2021, as Dan Apley pointed out during the break. You've been on the Robinhood train forever, Guy. Tim, collectively, we've done a decent job. People will say the runs, though.

29:00I don't think so. And And at the beginning of the early days of Robinhood, one of the things that I said, the only thing innovative was the name and the hair. And that was true because the stock was a disaster. But you know what? I think they've been humbled by the market and actually doing things right now. Now I think the stock is actually cheap. So analysts are behind the curve with that question. I think you're going to start seeing people raise their price targets in their earnings at the end of July. I think you stay with the name. The hair of the CEO is what you're referring to. He's now gone haircut.

29:26Right. You think it's coincidence? Oh, interesting. What does it do for Coinbase, though? if Robinhood's more competitive? I think Robinhood is more in line with me madness and markets that are all-time highs. And I wonder if the market was at 4 ,600, if Robinhood would be anywhere near here. So I think Coinbase, I continue to believe, OnRamp, there's so much more going on in the digital space to me that at least for now, they are one of the few places with the market share, with the reputation. And I think ultimately you're going to start to see some alleviation even of their legal headwinds because of the reality of what's going on with crypto assets.

30:06They're turning into securities. Yeah. But that also works for Robinhood, too. Right. So if you think about this acquisition and you think about where they want to play here, right, they're benefiting right now, of course, from this meme stuff. But if crypto turns into a real asset class that a lot more folks are going to be trading here in the U.S., then you look at their out year next year. They're like high single digits earnings and sales growth. They need to do something to reaccelerate growth. And this could be it. The flip side, though, is more and more people get into crypto assets and the volatility gets dampened and it makes it less fun to trade.

30:37What makes them any more, though, competitive in terms of, you know, whether it's hair and what was the other thing? The name of the company, which was clever. The name and the hair. So what do they have now versus the time they had the name and hair? I think it's fair. I mean, I think, listen, their growth, if you look at their asset growth, look at their customer growth, it's there. They announced a billion-dollar stock buyback, which at a$20 billion – at the time, actually,$17 billion valuation was pretty significant, I think. And it feels like they're operating better and they're starting to take shares.

31:06So I get it, though. I mean, valuation is expensive. I think they can still continue to grow. Coming up, a stealth rally in the home of the Dutch oven. What? Williams-Sonoma on a tear this year. What does it mean for the housing trade? We'll dig into that one next. A key hearing for Eli Lilly's potential Alzheimer's treatment is on the horizon inside the implications for this potentially groundbreaking drug right after this. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

31:48Welcome back to Fast Money. Eli Lilly is starting to an all-time high, even as the FDA weighs a more narrow approval than expected for the drugmaker's experimental Alzheimer's treatment or review board, set to give a recommendation for the drug on Monday. But briefing papers were released today. It shows that regulators are questioning whether Lilly's data excludes certain patient populations that would be needed for broader approval. For more on the looming decision, let's bring in NBC News medical contributor, Dr. Kavita Patel. Dr. Patel, great to see you as always. So this is going to be key in terms of what the total addressable market would be for this drug, donor.

32:22And so walk me through what the FDA could be weighing, because it sounds like it depends on the level of tau that patients might have. Right. Yeah, Melissa, that's exactly right. So let's talk about the efficacy, like the trailblazer trial, which Lily ran, showed that there was a significant reduction in the decline in generally early stage Alzheimer's patients. But when the FDA and their analysis kind of parsed that data, they saw that that's generally in people who had kind of a low to medium tau. Remember what tau is? That protein that is correlated with kind of the severity of Alzheimer's compared to people who might have more advanced Alzheimer's.

32:57Lilly made point to say, we don't think there should be a limitation and we still think we should have broad application for this drug. And they also brought up safety concerns. And that took a long time to kind of parse through because this has been an ongoing journey with Lilly to determine, was there a higher rate of death? In the end, the FDA analysis determined that there wasn't a significant change in the death rates between placebo and the drug. but there were higher rates of that amyloid-related imaging abnormality, more so than the other drug that's out there, Lakembi. So this could be, all in all, to your point, addressing the total addressable market, could cut into that depending on what the FDA does.

33:36How does this so far stack up to Lakembi? Because that's really the only competitor out there right now. Yeah, and here's where it gets even more interesting. It feels like this is like a, you know, unlike some of the conversations we have with Lillian, it's pretty straightforward. Here's the trials, Melissa. This is 30 years of Lilly trying to do something in kind of the memory space. And with Likambi in particular, when you stack it up with Dananamab, so Lilly, and kind of stacked up with the existing Alzheimer's drug, Likambi, it shows potentially that Lilly's is a little bit better in slowing that cognitive decline.

34:10But the twist, Lilly used their own assessment scale. They didn't use the standardized kind of cognitive assessment scale that you would normally have. and what they started the Trailblazer trial with. So Lilly makes the point that there's no difference between what they did and what other people have used in terms of scales. But it is going to be a conversation with the FDA. Having said all that, it does seem like this is on its track to approval. Will it have a lot of limits around it, certain tau, how much benefit to that kind of patient population with a higher tau level? I think that's the question they'll weigh.

34:45So the Biogen drug, Adjuhelm, Adjuhelm. I mean, it sort of feels like that where there was some controversy about the trial data and then eventually there was some concern about the price. It's now it's going to be discontinued. Should investors be concerned about an outcome like that where it is approved, but then there's always going to be second guessing about some of the data which they've had to revisit? You know, Melissa, I would have said that if this were the first, if Trailblazer was the first on the block. Now we have like three different trials, Adjuhelm, you have Lakembi, and you have this trailblazer data from Lilly.

35:19We have three trials that point to that amyloid plaque being kind of an important factor in Alzheimer's. When Agilhelm came out, remember, that was part of the controversy. Is this really significant? Was it something that you could look at clinically and make a determination of improvement in Alzheimer's? And now you're seeing kind of a repetition in that finding. And that is a positive for Lilly because it did show a clearing of that amyloid. And here's another difference. It showed a clearing. And in fact, the drug was stopped. That could be a differentiator for Lilly as well, because it's not a constant chronic drug.

35:53It stopped and they recommended stopping it when they cleared the amyloid plaque. Dr. P, it's Tim. Give us the timeline for what are the next catalyst, both for Biogen and Lilly here and try to help us understand also in a world where the call it the politics around the social dynamics of these stocks as it relates to pricing. and where this is, you know, this really is the holy grail right now, it seems to me. I mean, again, where these companies are going to have free reign to do what they need to do and what they want to do in terms of pricing. Right. Right. And I think, so first, where are we kind of in timeline?

36:27Look, this advisory committee is going to meet on June 10th soon. And then you'll see the FDA making a decision thereafter, shortly thereafter, we expect, because given how much time has gone on, because of the favorable profile where this is a time-limited drug, That is going to be very attractive, not just to patients, but to payers in terms of how they weigh, what the price might be. Let's compare that to Leukembian, what's happening there. They're already looking at a subcutaneous version of their drug that could be a much more convenient version to offer, making dosing more convenient, making it more convenient for patients in general.

37:01That's set to come out in 2025. So we're talking about probably having some important choices that you can make for early Alzheimer's patients as soon as as already at this point. But even more choices this year in terms of price and what I expect, you know, this is like it is the trillion dollar question. Just given the impact of Alzheimer's and how many people would be in this early phase, this could be exactly as you have heard Medicare say this could alone spike the premiums in Medicare. So this is going to be something that Medicare pricing and then all other commercial payers will be watching.

37:36And we'll be watching closely here, of course. But I think it'll be ongoing controversy. Kavita, thank you. Great to see you, Dr. Kavita Patel. Quick land, Eli Lilly guy, all time high today. Is this another leg higher? Well, Alzheimer's, Tim said, the holy grail without question and potentially, yes. But the one that's interesting quickly is Biogen. She mentioned it. Look at where it recently traded down to go back to September of 2022. A lot of bad news in the stock. There is no good news at this price in the stock. I think Biogen is actually interesting here. Coming up, don't look now, but shares of this purveyor of high-end home goods has more than doubled over the past year.

38:10What is feeling those games next? Fast Money is back in two.

38:20Welcome back to Fast Money. A stealth rally happening in shares of Williams-Sonoma recently. The home goods retailer has seen its stock more than double over the past year, and it is by far the best performer in the XHB home builder ETF in that time. Since the start of the pandemic, it jumped more than 440 percent. Tim, you brought this up on our call. We thought it was fascinating. Yeah, there are only so many Dutch ovens you can buy. And I think this is a case where if you look at the revenue profiling for the company on the top line, they're going to be flat over the next couple of years. I realize they grew year over year.

38:53If you look at the last quarter numbers up 32%, the multiple at 17 times, not expensive. But if you think about the environment we've had, and I'll get back to that long and variable lag and my view on discretionary. And this is where we are with a lot of these companies. I think Williams-Sonoma is such a well-run company. They've proven to be resilient. They've not been overly promotional. You can't tell me this company is going to be flat in terms of their top line over the next couple years and it's going to hold this multiple. In an environment where I think the consumer is more increasingly under pressure.

39:21Aren't there going to be more job vacancies? Aren't there going to be more people that I think are strained at the wallet? So it's been a great story. This move has been extraordinary. This is, you know, it's not a crypto stock. It's not an AI story. It was a$125 stock one year ago. It got up to$330 last week. It's down to$300. And I think you need to be thinking about where names and names like this. There's other discretionary names out there that look dangerous. Or is a Williams-Sonoma customer saving at Walmart and using the money to go buy an extra Dutch oven or Minecraft sheets, Lori? I think that's exactly what's happening, and I think the high-end consumer cares where their dollars go.

39:58They want a good experience and quality. All right. Coming up, GameStop surging nearly 50 % today. As Roaring Kitty makes waves again, the details driving the move next. Fast Money's back in two.

40:14Welcome back to Fast Money. Shares of GameStop jumping again today after yet another post from Roaring Kitty. Keith Gill announcing he will host a YouTube live stream tomorrow where he'll presumably discuss the stake in the stock. Gill's ability to cause such massive moves in these names has caught the attention of regulators. But the Wall Street Journal reporting that it is unlikely he could face prosecution as the SEC may not have enough evidence of market manipulation. What do they have? A cartoon that he tweeted? Well, that's what we brought up. I mean, listen, I find it unsavory. Again, I'm not a lawyer, but I don't think there's anything illegal.

40:49He posts a picture, people's interpretation of the picture, makes the stock go higher for whatever reason, and he's benefiting from it. I mean, it's gamesmanship like in baseball. If somebody steals the sign from the Mets, you're upset, but it's just the Mets sort of suck. I'm not saying you bring that up because the Yankees lost the World Series where there apparently was sign stealing, and we can't stop hearing about it because you guys continue to whine about it. I think if you consider the fact that full disclosure is kind of what he's giving. He's putting out an account. If that's not his account, that's a different issue, and I can't speak to that.

41:20But if someone is disclosing a position, isn't that what you're supposed to do? And then investors are able to make their decisions based upon that. Is he incented? Of course he's incented. But the disproportionate power this guy has over the market and this stock price is extraordinary. All right. Up next, final trades.

41:52Time for the final trade. Let's go around the horn. Tim. Boeing. I think we have a rebound in enthusiasm, but free cash will come in. Lori Calvacina, Energy, I like the valuations, the discipline, the buybacks. It all sounds good. Great to have you here on the desk. Thanks for having me. It was great. What she said on Energy, I'd say the OAH works, too. Guy? We are blessed here, as you know. Today's Thursday. A lot of us won't be here tomorrow. So we're doing this tonight. Chloe Cuff is our latest page, and she is unbelievable. And we were concerned because we've had a great run recently. There's no way.

42:27The bar was high. And you know what? She took it to the next level. Another prospect. Pantheon of pages. She's in the Parthenon with all the other people, without question. She's going on to do great things. We look forward to seeing her accomplishments. Thank you, Chloe. Biogen, Mel. Good luck at MSNBC, Chloe. Thanks for watching Fast Money. Mad Money with Jim Cramer starts right now.

42:58NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit CNBC.com forward slash fast money disclaimer.

From the publisher

Commodities rising across the board, as oil, metals, and agricultural prices all climb. But as those all head higher, rates continue to fall. What the moves could be saying about the market. Plus Eli Lilly’s Alzheimer’s treatment raising some eyebrows at the FDA. What regulators are flagging, and how it could impact the future of the drug.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Rates And Commodities Diverge… Plus Lilly’s Latest Drug Concerns 6/6/24CNBC's "Fast Money" · 44 min
Listen in VO